Coya yesterday reported their low dose Il-2 phase 2 Alzheimer's results. Seems mixed results with lower dosage of treatment every four weeks providing a slowing in cognitive decline. Meanwhile, higher dosage of treatment every two weeks appeared no better than placebo. Stock down 28% on the news.

Coya announced the results of the investigator initiated trial simultaneously with the conference poster.

https://ir.coyatherapeutics.com/news/news-det...fault.aspx